Fulton Bank N.A. Sells 2,364 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fulton Bank N.A. decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 47.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,605 shares of the medical research company’s stock after selling 2,364 shares during the period. Fulton Bank N.A.’s holdings in IQVIA were worth $512,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Private Trust Co. NA raised its holdings in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after purchasing an additional 47 shares during the period. Clear Harbor Asset Management LLC grew its position in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co increased its position in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares during the period. Fortitude Family Office LLC increased its holdings in IQVIA by 2.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after acquiring an additional 56 shares during the period. Finally, Huntington National Bank raised its position in shares of IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after buying an additional 56 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.8 %

Shares of NYSE IQV opened at $204.26 on Friday. The firm has a fifty day simple moving average of $201.95 and a two-hundred day simple moving average of $221.69. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $37.07 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. BTIG Research cut their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.